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Background: Data evaluating the chronological order of appearance of extraintestinal manifestations (EIMs) relative to the time of inﬂammatory bowel
disease (IBD) diagnosis is currently lacking. We aimed to assess the type, frequency, and chronological order of appearance of EIMs in patients with IBD.
Methods: Data from the Swiss Inﬂammatory Bowel Disease Cohort Study were analyzed.
Results: The data on 1249 patients were analyzed (49.8% female, median age: 40 [interquartile range, 30–51 yr], 735 [58.8%] with Crohn’s disease,
483 [38.7%] with ulcerative colitis, and 31 [2.5%] with indeterminate colitis). A total of 366 patients presented with EIMs (29.3%). Of those, 63.4%
presented with 1, 26.5% with 2, 4.9% with 3, 2.5% with 4, and 2.7% with 5 EIMs during their lifetime. Patients presented with the following diseases as
ﬁrst EIMs: peripheral arthritis 70.0%, aphthous stomatitis 21.6%, axial arthropathy/ankylosing spondylitis 16.4%, uveitis 13.7%, erythema nodosum
12.6%, primary sclerosing cholangitis 6.6%, pyoderma gangrenosum 4.9%, and psoriasis 2.7%. In 25.8% of cases, patients presented with their ﬁrst EIM
before IBD was diagnosed (median time 5 mo before IBD diagnosis: range, 0–25 mo), and in 74.2% of cases, the ﬁrst EIM manifested itself after IBD
diagnosis (median: 92 mo; range, 29–183 mo).
Conclusions: In one quarter of patients with IBD, EIMs appeared before the time of IBD diagnosis. Occurrence of EIMs should prompt physicians to
look for potential underlying IBD.
(Inﬂamm Bowel Dis 2015;21:1794–1800)
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C rohn’s disease (CD) and ulcerative colitis (UC) represent themain entities of inﬂammatory bowel diseases (IBDs). Dur-
ing their lifetime, patients with IBD are likely to suffer from
extraintestinal manifestations (EIMs), which are reported with
frequencies ranging from 6% to 47%.1–8 The occurrence of EIM
can considerably affect morbidity and mortality in patients with
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IBD.9,10 EIMs are classiﬁed into 3 major groups. The ﬁrst one
includes manifestations that are either associated with intestinal
disease activity (peripheral arthritis, erythema nodosum, oral aph-
thous ulcers) or not (pyoderma gangrenosum, uveitis, spondy-
larthropathy, primary sclerosing cholangitis [PSC]).11 The
second category of EIMs encompasses non–IBD-speciﬁc autoim-
mune diseases, such as thyroid disease, hemolytic anemia, viti-
ligo, or insulin-dependent diabetes mellitus. The third group
includes IBD-related complications that are attributed to anatom-
ical or metabolic abnormalities, such as osteopathy, nephrolithia-
sis, or thromboembolic events.
Most patients with CD and UC suffering from EIMs also
present with extensive colitis and are likely to have a positive IBD
family history.8,12 Most EIMs tend to follow the clinical course of
IBD, with the exception of axial arthropathy/ankylosing spondy-
litis, PSC, pyoderma gangrenosum, and uveitis.8,13–16 We have
recently reported that about one quarter of EIM-affected IBD
patients tend to suffer from a combination of several EIMs during
their disease course (up to 5 EIMs).8 It seems that the appearance
of 1 EIM increases the susceptibility to developing other EIMs.8
The skin, joints, the biliary tract, as well as the eyes represent the
organs most commonly affected by EIM. The high frequency with
which these 4 organs are involved suggests a common pathogenic
link; however, the underlying mechanisms are yet not completely
understood.9
Despite the fact that EIMs are frequently observed in
patients with IBD, data on the frequency of EIMs in large IBD
populations are scarce. Furthermore, studies evaluating the
chronological order of appearance of EIMs relative to the time
of IBD diagnosis are lacking. As such, the proportion of patients
presenting with EIMs before or after the time of IBD diagnosis
has not been elucidated. The data about EIMs that precede the
time of IBD diagnosis are of particular interest, since appearance
of EIMs may help treating physicians to detect IBD and in doing
so shorten the diagnostic delay.17
We aimed to determine the frequency of patients affected
by EIM(s) before and after the time of IBD diagnosis and to assess
the cumulative risk of developing one or several EIMs relative to
the time of IBD diagnosis in a large national cohort of patients
with IBD.
MATERIALS AND METHODS
Patients
The Swiss IBD Cohort Study (SIBDCS) has been including
patients with IBD meeting the diagnostic criteria according to the
established guidelines from all regions of Switzerland starting in
2006.18,19 The SIBDCS is supported by the Swiss National Sci-
ence Foundation and approved by local ethics committees of the
participating centers.20 For inclusion, patients need to provide
written informed consent. Patients also need to have a permanent
residency status in Switzerland and/or else need to be covered by
a Swiss health insurance. Patients can be included into the cohort
if the diagnosis of CD, UC, or indeterminate colitis (IC) was
established at least 4 months before inclusion, or if they had at
least 1 episode of symptom recurrence.20 At the time of inclusion,
patients undergo a thorough clinical and laboratory assessment.
Clinical, socioeconomic, and psychosocial data are collected.
Detailed physician questionnaires are completed by patients’
treating physicians, and patient-reported outcome questionnaires
that, among other things, assess quality of life, the degree of social
impairment and symptom severity, are completed by patients
themselves. Patients were recruited in 5 University hospitals
and 2 large private practices throughout Switzerland.
Deﬁnitions for EIMs
All EIMs were diagnosed by a physician. The following
EIMs were analyzed: peripheral arthritis, axial arthropathy/ankylos-
ing spondylitis, aphthous stomatitis, uveitis, erythema nodosum,
pyoderma gangrenosum, psoriasis, and PSC.11,17,21–23 Rheumato-
logic EIMs were diagnosed by a rheumatologist. Peripheral arthritis
was deﬁned as pain, swelling, and/or redness in one or several
peripheral joints. Axial arthropathy/ankylosing spondylitis was diag-
nosed based on a combination of typical symptoms, characteristic
clinical ﬁndings, as well as x-ray examination. All patients with
uveitis were diagnosed by an ophthalmologist. Erythema nodosum
was diagnosed when tender bluish-red nodules (mainly on the
extensor side of the limbs) were found, and pyoderma gangrenosum
was diagnosed when typical chronic ulcers with undermined
necrotic bluish margins (many of them beginning as pustular or
nodular lesions) persisted for several weeks or longer. The skin
lesions were diagnosed by dermatologists. PSC was diagnosed
based on characteristic alterations of the biliary tract in endoscopic
retrograde cholangiography and/or magnetic resonance cholangiog-
raphy. Oral aphthous ulcers were diagnosed by the treating
gastroenterologists.
METHODS
Data were entered into a Microsoft Access database
(Access 2000; Microsoft Switzerland Ltd. Liab. Co., Wallisellen,
Switzerland). The questionnaires were sent to the datacenter of the
SIBDCS at the Institute of Social and Preventive Medicine,
University of Lausanne, Switzerland. All data were validated by
the data manager, and rigorous rules were applied to ensure data
quality.
A standardized questionnaire, which included items on
demographic characteristics, onset of symptoms, date of diagno-
sis, extent of disease, family history of IBD, smoking status, the
results of laboratory tests, current therapy, and medical history
(drugs, complications, and surgery), was completed by the
treating physician. In addition, the standardized questionnaire
assessed whether patients with IBD had ever experienced any
kind of EIM, and whether the EIM(s) was/were present at the time
of inclusion. The disease location was grouped according to the
Montréal classiﬁcation. For CD, L1 denotes disease in the termi-
nal ileum, L2 denotes disease in the colon, L3 denotes ileocolonic
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disease, and L4 denotes isolated disease in the upper gastrointes-
tinal tract.24 For UC, E1 denotes rectal disease, E2 denotes
left-sided colitis, and E3 denotes extensive colitis. Since the infor-
mation on the chronological order of appearance of EIM relative
to the time of IBD diagnosis was not captured by the standardized
questionnaires, 2 medical students (C.G. and M.S.) visited IBD
centers, in which patients were included, and reviewed patient
ﬁles to complete, together with the treating physician, an addi-
tional questionnaire that included items on various characteristics
of EIMs. Only patients with all chronologic information regarding
the appearance of EIM relative to IBD diagnosis were included.
This work was performed under supervision of S.R.V. and A.M.
S., who also validated all data obtained using this additional ques-
tionnaire. For the purposes of this study, data on 1249 patients
with IBD, enrolled into the SIBDCS between January 2006 and
March 2010, were analyzed.
Statistical Analysis
All statistical analyses were performed using the statistical
package program Stata (version 12.1, StataCorp, College Station,
TX). Quantitative data distribution was analyzed using Normal-QQ-
Plots. Results of quantitative data are presented either as mean 6
SD and range (for Gaussian data) or median, interquartile range, and
range (for non-Gaussian data). Categorical data were summarized as
the percentage of the group total. Differences in categorical data
distribution between groups were assessed using the chi-square test,
or the Fisher’s exact test in case of insufﬁcient sample size.
Survival curves were calculated according to the Kaplan–
Meier method to estimate probability of staying EIM free accord-
ing to time from IBD diagnosis. A P value ,0.05 was considered
statistically signiﬁcant.
RESULTS
Clinical Characteristics of the
Study Population
Of the 1249 patients with IBD included in the study, 735
patients (58.8%) had CD, 483 patients (38.7%) had UC, and 31
patients (2.5%) had IC. Six hundred twenty-two patients were female
(49.8%) with a median age at enrollment of 40 years (interquartile
range, 30–51 yr). The clinical characteristics as well as disease loca-
tion and current medication status of the study patients are shown in
Table, Supplemental Digital Content 1, http://links.lww.com/IBD/
A874. The clinical characteristics of 366 patients (248 patients with
CD, 105 patients with UC, 13 patients with IC) that presented with
one or more EIMs (up to 5) are depicted in Table 1.
Frequencies and Types of EIM in the
Study Population
Two hundred forty-eight patients with CD (33.7%), 105
patients with UC (21.7%), and 13 patients with IC (41.9%)
suffered from at least 1 EIM that occurred either before or after
the time of IBD diagnosis (Table 2). The maximum number of
TABLE 1. Characteristics of Patient Affected by One or More EIMs
CD UC IC IBD Total
No. patients 248 105 13 366
No. females (%) 151 (60.9) 52 (49.5) 9 (69.2) 212 (57.9)
Median age at enrollment (in yr) 41 41 38 41
Interquartile range 29–50 32–50 29–49 30–50
Range 16–77 17–82 20–71 16–82
Median disease duration (in yr) 9 9 4 8
Interquartile range 3–16 4–15 1–7 3–16
Range 0–52 0–49 0–10 0–52
Disease location, n (%) L1: 66 (26.6) E1: 13 (12.4)
L2: 91 (36.7) E2: 40 (38.1)
L3: 81 (32.7) E3: 47 (44.8)
L4: 2 (0.8)
Missing: 8 (3.2) Missing: 5 (4.7)
Medication (ever treated), n (%)
5-ASA 152 (61.3) 98 (93.3) 12 (92.3) 262 (71.6)
Steroids systemic 184 (74.2) 85 (81.0) 12 (92.3) 281 (76.8)
Budesonide 77 (31.0) 11 (10.5) 0 (0.0) 88 (24.0)
Azathioprine/6-MP 195 (78.6) 64 (61.0) 8 (61.5) 267 (73.0)
Methotrexate 72 (29.0) 13 (12.4) 2 (15.4) 87 (23.8)
TNF-antagonists 129 (52.0) 22 (21.0) 5 (38.5) 156 (42.6)
Cyclosporine/tacrolimus 5 (2.0) 10 (9.5) 1 (7.8) 16 (4.4)
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EIMs was 5 (9 patients with CD and 1 patient with UC). Of 248
patients with CD with EIM, 60.9% had 1 EIM, 27.8% had 2 EIM,
4.8% had 3 EIM, 2.8% had 4 EIM, and 3.6% had 5 EIM. During the
course of their disease, 105 patients with UC who ever presented
with EIMs suffered from 1 (66.7%), 2 (24.8%), 3 (5.7%), 4 (1.9%),
or 5 EIMs (1.0%). In all patients with IBD with EIMs, peripheral
arthritis was the most prevalent (70.0%), followed by aphthous
stomatitis (21.6%), axial arthropathy/ankylosing spondylitis
(16.4%), uveitis (13.7%), erythema nodosum (12.6%), pyoderma
gangrenosum (4.9%), PSC (6.0%), and psoriasis (2.7%).
Distribution of Different EIMs According to
Their Chronological Appearance
The 3 most frequent EIMs, which were likely to appear as
ﬁrst EIM (N ¼ 232) were peripheral arthritis (65%), axial arthrop-
athy/ankylosing spondylitis (6.3%), and aphthous stomatitis
(6.6%). If patients were diagnosed with a second EIM (N ¼
97), aphthous stomatitis (25.4%), uveitis (20.9%), and axial
arthropathy/ankylosing spondylitis (15.7%) were the most fre-
quent EIM in our cohort. The most prevalent EIMs that were
likely to appear as a third EIM (N ¼ 18 affected patients) were
aphthous stomatitis (32.4%) followed by erythema nodosum
(29.7%) and axial arthropathy/ankylosing spondylitis (13.5%).
We then examined the time intervals in which the EIMs
appeared before and/or after the time of IBD diagnosis. Figure 1
illustrates the chronological order of appearance of different EIMs
in relation to the time of IBD diagnosis. Peripheral arthritis was
diagnosed before the time of IBD diagnosis in 19.7% of patients.
Axial arthropathy/ankylosing spondylitis was diagnosed in 39.1%
of patients before IBD was diagnosed. Of note, the 25th percentile
for axial arthropathy/ankylosing spondylitis lies at minus 2
months related to IBD diagnosis. Furthermore, 5 patients
experienced axial arthropathy/ankylosing spondylitis during the
same month IBD was diagnosed. Aphthous stomatitis was diag-
nosed before IBD in 27.8% of patients, uveitis in 52.2% of pa-
tients, erythema nodosum in 14.3% of patients, pyoderma
gangrenosum in 14.3% of patients, psoriasis in 50% of patients,
and PSC in 23.8% of patients. Of note, musculoskeletal and der-
matologic EIMs more frequently appeared after the time of IBD
diagnosis rather than before (P ¼ 0.010).
The Kaplan–Meier survival curves indicate the probability
of staying free of EIMs in patients with CD and UC (1218 patients
in total) over time (Fig. 2A). EIMs were more prevalent in
TABLE 2. Frequency and Type of EIMs in the IBD Population Examined
CD UC IC IBD Total
EIM frequency 248 105 13 366
No. EIM(s) per patient, n (%)
1 151 (60.9) 70 (66.7) 11 (84.6) 232 (63.4)
Two 69 (27.8) 26 (24.8) 2 (15.4) 97 (26.5)
Three 12 (4.8) 6 (5.7) 0 (0.0) 18 (4.9)
Four 7 (2.8) 2 (1.9) 0 (0.0) 9 (2.5)
Five 9 (3.6) 1 (1.0) 0 (0.0) 10 (2.7)
Type of EIM, n (%)
Arthritis 184 (74.2) 62 (59.1) 10 (76.9) 256 (70.0)
Aphthous stomatitis 58 (23.4) 19 (18.1) 2 (15.4) 79 (21.6)
Axial arthropathy/ankylosing spondylitis 45 (18.2) 14 (13.3) 1 (7.7) 60 (16.4)
Uveitis 39 (15.7) 11 (10.5) 0 (0.0) 50 (13.7)
Erythema nodosum 31 (12.5) 13 (12.4) 2 (15.4) 46 (12.6)
Pyoderma gangrenosum 9 (3.6) 9 (8.6) 0 (0.0) 18 (4.9)
Psoriasis 7 (2.8) 3 (2.9) 0 (0.0) 10 (2.7)
PSC 5 (2.0) 19 (18.1) 0 (0.0) 24 (6.6)
FIGURE 1. Appearance of different EIM relative to the time of IBD
diagnosis. Data are presented as horizontal boxplots. The box com-
prises the 25th and 75% percentile; the vertical line in the box cor-
responds to the median.
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FIGURE 2. (A), EIM-free survival (total of 1218 patients): CD (blue curve) and UC (red curve). Kaplan–Meier estimates for all EIM (panel A), for
arthritis (panel B), for axial arthropathy/ankylosing spondylitis (panel C), and for PSC (Panel D). (B), EIM-free survival (total 1218 patients with IBD):
CD (blue curve) and UC (red curve). Kaplan–Meier estimates for aphthous stomatitis (panel E), for uveitis/iritis (panel F), for erythema nodosum
(panel G), and for pyoderma gangrenosum (panel H).
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patients with CD when compared with patients with UC (Fig.
2A). Only PSC (Fig. 2D) and pyoderma gangrenosum (Fig. 2H)
occurred more often in patients with UC. Peripheral arthritis (Fig.
2B) and axial arthropathy/ankylosing spondylitis (Fig. 2C) were
the most prevalent EIMs in our cohort of patients with IBD. After
30 years of disease duration, 54.0% of patients with CD and
73.0% of patients with UC were free of peripheral arthritis.
DISCUSSION
In this large cohort study, we report on the chronologic
occurrence of different EIMs relative to the time of IBD
diagnosis. EIMs are common in patients with IBD, and we
demonstrate that EIMs can appear in one quarter of patients
before IBD is diagnosed.
In accordance with data from Veloso et al and our previous
study, we found a higher frequency of EIMs in patients with CD
compared with patients with UC.7,8 Veloso et al did not differen-
tiate between the different types of EIM over time but pooled
them together to evaluate the EIM prevalence during a 20-year
follow-up period. Lakatos et al25 evaluated 873 Hungarian pa-
tients with IBD (254 patients with CD, average disease duration
9.2 yr; 619 patients with UC, average disease duration 11.2 yr)
and found that a total of 21.3% had EIM (UC: 15.0%, CD:
36.6%). Although the disease duration between the Hungarian
cohort and the Swiss cohort was comparable, we observed a higher
EIM frequency in our cohort, particularly regarding the joint
manifestations.
Importantly, we found that in one quarter of patients, the
EIM appeared before IBD was diagnosed. When analyzing the
speciﬁc EIM, we found that peripheral arthritis (in 19.7%), axial
arthropathy/ankylosing spondylitis (in 39.1%), aphthous stomati-
tis (in 27.8%), uveitis (in 52.2%), erythema nodosum (in 14.3%),
pyoderma gangrenosum (in 14.3%), psoriasis (in 50%), and PSC
(in 23.8%) all may appear before IBD is diagnosed. This ﬁnding
has important clinical implications since the awareness of this fact
might decrease the diagnostic delay in patients with IBD. We
recently showed that diagnostic delay is a particular concern
especially in patients with CD where one fourth of patients require
.24 months from symptoms onset until CD diagnosis are estab-
lished.17 This ﬁnding is of particular importance since during this
period bowel damage can already occur.26
The development of 1 EIM appears to increase the
susceptibility of developing other EIM.27 An overlap of EIM
has particularly been observed with peripheral arthritis, erythema
nodosum, affections of the biliary tract, and the eyes, which sup-
port the hypothesis of a common pathogenic pathway. Supporting
that concept, Bhagat et al28 reported an autoimmune reaction
toward an isoform of tropomyosin (tropomyosin-related peptide),
which is expressed in the eye (nonpigmented ciliary epithelium),
skin (keratinocytes), joints (chondrocytes), biliary epithelium, and
the gut. We found a relevant proportion of our patients with CD
and UC suffering from several (up to 5) EIM; the prevalence of
multiple EIM was again higher in patients with CD compared
with patients with UC. Genetic analyses may help understanding
the increased risk for multiple EIM in some patients. Patients with
UC who display HLA-B8, DR3 phenotype were found to have
a 10-fold higher risk of PSC,29 and patients with UC with HLA
DRB1*0103 (DR103) had a higher risk of ocular and articular
manifestations.30
Our study has several strengths and also limitations. We
report in a large cohort study, including a detailed additional chart
review, on the chronologic appearance between EIM and IBD
diagnosis. We further depict the cumulative risk of developing
one or several EIM relative to the time of IBD diagnosis. Besides
the large patient sample size, the prospective patient inclusion
using physician questionnaires is probably less prone to under-
reporting of EIM prevalence compared with databases where EIM
are retrospectively identiﬁed using the International Classiﬁca-
tion of Diseases codes. A potential limitation may be that the
Swiss IBD cohort is not population based; some selection bias
is therefore likely to be present. For instance, patients included by
private practitioners are underrepresented compared with patients
included by hospitals (20% of patients with IBD are recruited by
colleagues in private practice compared with 80% of patients
recruited by physicians working in hospitals). Furthermore, the
relative number of patients suffering from EIM is lower in this
study (29.3%) when compared with our previously published
study (38.1%).8 This is related to the fact that in this study, only
patients with known chronologic appearance between EIM and
IBD diagnosis were included.
In summary, we demonstrate in a large national cohort that
EIMs are frequent and appear in one quarter of patients before
IBD is diagnosed. Knowledge of this phenomenon may result in
increased awareness for underlying IBD, thereby facilitating
diagnosis and reducing diagnostic delay.
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